ESMO News

FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies

noreply@esmo.org — Wed, 12 Aug 2026 07:08:00 +00:00

Evidence for efficacy is based on the results from the Precision-T study

Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC

noreply@esmo.org — Tue, 11 Aug 2026 07:08:00 +00:00

Findings from the COMMIT study

Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism

noreply@esmo.org — Mon, 10 Aug 2026 07:08:00 +00:00

Findings from the Hydra study

EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength

noreply@esmo.org — Fri, 07 Aug 2026 07:08:00 +00:00

New indication concerns a monotherapy in paediatric patients with CP-CML who are resistant or intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or who have the T315I mutation

Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL

noreply@esmo.org — Thu, 06 Aug 2026 07:08:00 +00:00

Findings from the BRUIN CLL-322 study

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC

noreply@esmo.org — Wed, 05 Aug 2026 07:08:00 +00:00

Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies

Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels

noreply@esmo.org — Tue, 04 Aug 2026 07:08:00 +00:00

Findings from the RxPONDER study

Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response

noreply@esmo.org — Mon, 03 Aug 2026 07:08:00 +00:00

Findings from the Neo-CheckRay study

EMA Recommends Extension of Therapeutic Indications for Serplulimab

noreply@esmo.org — Fri, 31 Jul 2026 07:07:00 +00:00

New indication concerns a combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with unresectable, locally advanced or metastatic squamous NSCLC

Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer

noreply@esmo.org — Thu, 30 Jul 2026 07:07:00 +00:00

Findings from the CIRCULATE, an AIO (KRK-0217)/ABCSG study

FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC

noreply@esmo.org — Wed, 29 Jul 2026 07:07:00 +00:00

Evidence for efficacy is based on the results from the PATINA study

Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs

noreply@esmo.org — Tue, 28 Jul 2026 07:07:00 +00:00

Findings from the COMPETE study

Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC

noreply@esmo.org — Mon, 27 Jul 2026 07:07:00 +00:00

Findings from the ELEVATE study

EMA Recommends Extension of Therapeutic Indications for Epcoritamab

noreply@esmo.org — Fri, 24 Jul 2026 07:07:00 +00:00

New indication concerns a combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma

Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Thu, 23 Jul 2026 07:07:00 +00:00

Findings from the BREAKWATER Cohort 3 study

FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma

noreply@esmo.org — Wed, 22 Jul 2026 07:07:00 +00:00

Evidence for efficacy is based on the results from the LITESPARK-022 study

Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence

noreply@esmo.org — Tue, 21 Jul 2026 07:07:00 +00:00

Findings from the LITESPARK-022 study

Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and Advertising Legislation

noreply@esmo.org — Mon, 20 Jul 2026 07:07:00 +00:00

Given that up to 40% of all cancers are preventable, robust tobacco cessation policies are among the most effective strategies for reducing the risk of cancer, improving human health, and reducing cancer cases

Temporary Interruption of Endocrine Therapy for Pregnancy, Including Use of Fertility Preservation, Does Not Increase Risk of Breast Cancer Events in Women with HR-positive Breast Cancer

noreply@esmo.org — Mon, 20 Jul 2026 07:07:00 +00:00

Updated findings from the POSITIVE study

EMA Recommends Extension of Therapeutic Indications for Pembrolizumab

noreply@esmo.org — Fri, 17 Jul 2026 07:07:00 +00:00

New indications concern treatment of adult patients with resectable muscle invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy and treatment of adolescents with melanoma and relapsed or refractory classical Hodgkin lymphoma